Investing IdeasBrowse All StocksMarkets
Have your own idea? Try our Stock Screener
Header cover image

U.S. Healthcare Services Industry Analysis

UpdatedApr 05, 2026
DataAggregated Company Financials
Companies102
  • 7D3.3%
  • 3M-6.1%
  • 1Y1.4%
  • YTDn/a

In the last week, the Healthcare Services industry is up 3.3%, with CVS Health up 4.9%. In the same time, DaVita was down 5.7%. Overall in the last year, the industry is flat. As for the next few years, earnings are expected to grow by 19% per annum.

Industry Valuation and Performance

Has the U.S. Healthcare Services Industry valuation changed over the past few years?

DateMarket CapRevenueEarningsPEAbsolute PEPS
Sun, 05 Apr 2026US$284.1bUS$774.9bUS$9.9b27.3x28.7x0.4x
Tue, 03 Mar 2026US$302.5bUS$772.1bUS$9.7b25.4x31.1x0.4x
Thu, 29 Jan 2026US$287.2bUS$755.9bUS$8.6b27.1x33.6x0.4x
Sat, 27 Dec 2025US$298.0bUS$755.9bUS$8.6b27x34.8x0.4x
Mon, 24 Nov 2025US$301.6bUS$755.8bUS$8.6b31.4x35.1x0.4x
Wed, 22 Oct 2025US$314.2bUS$740.5bUS$11.4b30.9x27.5x0.4x
Fri, 19 Sep 2025US$297.1bUS$740.1bUS$11.4b24x26.1x0.4x
Sun, 17 Aug 2025US$286.6bUS$740.4bUS$11.3b23.3x25.3x0.4x
Tue, 15 Jul 2025US$281.0bUS$727.3bUS$12.5b24.6x22.6x0.4x
Thu, 12 Jun 2025US$289.9bUS$727.3bUS$12.3b25.9x23.6x0.4x
Sat, 10 May 2025US$294.0bUS$726.3bUS$12.3b26.9x24x0.4x
Mon, 07 Apr 2025US$277.9bUS$710.7bUS$9.5b27.6x29.3x0.4x
Wed, 05 Mar 2025US$286.1bUS$709.8bUS$9.5b28.8x30.2x0.4x
Fri, 31 Jan 2025US$276.5bUS$704.4bUS$9.3b27.8x29.7x0.4x
Sun, 29 Dec 2024US$245.4bUS$686.8bUS$7.9b25.7x31.1x0.4x
Tue, 26 Nov 2024US$282.4bUS$686.8bUS$7.9b30.5x35.9x0.4x
Thu, 24 Oct 2024US$281.0bUS$667.9bUS$10.6b34.1x26.4x0.4x
Sat, 21 Sep 2024US$293.7bUS$667.5bUS$10.6b33.9x27.8x0.4x
Mon, 19 Aug 2024US$285.6bUS$667.5bUS$10.5b34.1x27.2x0.4x
Wed, 17 Jul 2024US$279.3bUS$654.3bUS$10.2b31.3x27.4x0.4x
Fri, 14 Jun 2024US$280.0bUS$654.3bUS$10.2b28.6x27.5x0.4x
Sun, 12 May 2024US$277.1bUS$654.3bUS$10.4b27.1x26.7x0.4x
Tue, 09 Apr 2024US$308.9bUS$642.9bUS$11.7b31.5x26.3x0.5x
Thu, 07 Mar 2024US$303.1bUS$643.0bUS$13.0b35.3x23.4x0.5x
Sat, 03 Feb 2024US$315.4bUS$634.2bUS$13.6b35.2x23.2x0.5x
Mon, 01 Jan 2024US$321.0bUS$625.8bUS$13.8b33.5x23.3x0.5x
Wed, 29 Nov 2023US$298.1bUS$625.6bUS$13.7b33.7x21.7x0.5x
Fri, 27 Oct 2023US$302.4bUS$612.3bUS$8.7b28x34.8x0.5x
Sun, 24 Sep 2023US$308.3bUS$611.1bUS$8.8b26.3x34.9x0.5x
Tue, 22 Aug 2023US$305.4bUS$610.7bUS$8.7b27.6x35.2x0.5x
Thu, 20 Jul 2023US$324.7bUS$598.1bUS$10.4b27.9x31.2x0.5x
Sat, 17 Jun 2023US$307.0bUS$598.0bUS$10.1b27.9x30.3x0.5x
Mon, 15 May 2023US$300.8bUS$598.2bUS$10.1b24.9x29.7x0.5x
Wed, 12 Apr 2023US$318.9bUS$586.9bUS$11.0b22.8x29x0.5x
Price to Earnings Ratio

29x


Total Market Cap: US$318.9bTotal Earnings: US$11.0bTotal Revenue: US$586.9bTotal Market Cap vs Earnings and Revenue0%0%0%
U.S. Healthcare Services Industry Price to Earnings3Y Average 28.7x202420252026
Current Industry PE
  • Investors are relatively neutral on the American Healthcare Services industry at the moment, indicating that they anticipate long term growth rates to remain steady.
  • The industry is trading close to its 3-year average PE ratio of 28.7x.
  • The industry is trading close to its 3-year average PS ratio of 0.44x.
Past Earnings Growth
  • The earnings for companies in the Healthcare Services industry have declined 3.4% per year over the last three years.
  • Meanwhile revenues for these companies have grown 9.7% per year.
  • This means that although more sales are being generated, either the cost of doing business or the level of investment back into businesses has increased, which has decreased profits.

Industry Comparison

How does U.S. Healthcare Services compare with similar industries?

US Market3.46%
Healthcare3.50%
Healthcare Services4.45%
Healthcare Services3.31%
Managed Healthcare6.54%
Healthcare Distributors3.58%
Healthcare Facilities-0.79%
Industry PEThere are no additional sub-industries under this industry.
Forecasted GrowthThere are no additional sub-industries under this industry.

Top Stock Gainers and Losers

Which companies have driven the market over the last 7 days?

CompanyLast Price7D1YValuation
CVS CVS HealthUS$73.494.9%
+US$4.3b		15.4%PE52.9x
CI Cigna GroupUS$270.023.1%
+US$2.1b		-16.2%PE12x
GH Guardant HealthUS$93.8310.9%
+US$1.2b		131.2%PS12.5x
LH Labcorp HoldingsUS$273.723.6%
+US$784.4m		21.7%PE25.7x
BLLN BillionToOneUS$79.3614.1%
+US$450.9m		n/aPE1249.7x

Latest News

CCRN
US$9.18
Cross Country Healthcare
7D
-3.6%
1Y
-36.7%

CCRN: Margin Execution And Travel Nurse Demand Will Drive Bullish Thesis

Analysts have nudged their price targets for Cross Country Healthcare higher, with moves such as UBS lifting its target to $10 from $9 and Benchmark setting a $14 target. They cited improving travel nurse demand, confidence in a 4% to 5% adjusted EBITDA margin target by the end of 2026, and a clearer path toward higher margin segments and operating leverage.
HIMS
US$19.14
Hims & Hers Health
7D
-1.2%
1Y
-26.4%

HIMS: Renewed GLP 1 Partnership Will Shape Future Upside Potential

The analyst price target for Hims & Hers Health has moved slightly higher to about $24, as analysts factor in updated views on GLP-1 partnerships, reduced litigation risk, and mixed reactions to recent guidance updates. Analyst Commentary Recent research views on Hims & Hers Health show a wide range of opinions, with some firms lifting targets and ratings on the back of the Novo Nordisk partnership and GLP-1 potential, while others remain cautious after prior guidance updates, litigation concerns, and questions around compounded GLP-1 products.
CI
US$270.02
Cigna Group
7D
3.1%
1Y
-16.2%

CI: Leadership Transition And Onsite Care Expansion Will Drive Future Upside

Analysts have slightly refined their view on Cigna Group, trimming the price target by a fraction to $338.79 as updated assumptions for revenue growth, profit margins, and future P/E bring the model into closer alignment with their latest expectations. What's in the News Cigna Group plans a leadership transition, with David M.
ADUS
US$91.59
Addus HomeCare
7D
-3.8%
1Y
-8.7%

ADUS: Secular Tailwinds And Acquisitions Will Support Future Upside Despite Cautious Sentiment

Analysts have nudged their price targets for Addus HomeCare lower, with recent cuts of $5 to $10 from firms such as Barclays and Stephens contributing to a reduced implied fair value of about $110. This comes even as updated models reflect slightly higher revenue growth and profit margin assumptions, paired with a more conservative future P/E multiple.
LH
US$273.72
Labcorp Holdings
7D
3.6%
1Y
21.7%

LH: Expanded Cancer And Alzheimer’s Testing Will Support Future Upside

Analysts kept their average price target for Labcorp Holdings steady at about $307.71. This reflects unchanged views on fair value, discount rate, revenue growth, profit margin, and future P/E assumptions.
AMN
US$18.20
AMN Healthcare Services
7D
-3.8%
1Y
-10.7%

AMN: Strike Staffing Strength And Industry Stabilization Will Offset Ongoing Margin Constraints

Analysts have lifted the fair value estimate for AMN Healthcare Services from $17.00 to $19.50 as they factor in higher price targets across the Street, expectations for industry stabilization, and the company's role in large scale labor disruption staffing. Analyst Commentary Recent research highlights a split view on AMN Healthcare Services, with some firms lifting price targets while others flag risks tied to execution, growth visibility, and reliance on strike related revenue.
WGS
US$66.20
GeneDx Holdings
7D
16.0%
1Y
-17.3%
DGX
US$198.02
Quest Diagnostics
7D
1.3%
1Y
20.6%
GRDN
US$37.99
Guardian Pharmacy Services
7D
11.2%
1Y
78.8%
GH
US$93.83
Guardant Health
7D
10.9%
1Y
131.2%

GH: Future Upside Will Depend On Executing 2026 Screening Expansion

Guardant Health's blended analyst price target is now aligned around $130, as multiple firms raised targets into a roughly $110 to $150 range. They cited strong recent execution, momentum across therapy selection, MRD and screening, and 2026 guidance that analysts view as supported by prior launches and an improved balance sheet.
RDNT
US$54.79
RadNet
7D
-2.4%
1Y
12.5%

RDNT: Outpatient Imaging Shift And AI Adoption Will Drive Future Upside

Analysts kept their $92 price target for RadNet unchanged, citing what they see as attractive long term growth drivers in outpatient diagnostic imaging, reasonable 2025 to 2028 company targets, supportive Medicare reimbursement trends, potential capital deployment benefits, and expected AI contributions. Analyst Commentary Bullish Takeaways Bullish analysts view outpatient diagnostic imaging as an attractive subsector, with hospital to outpatient shifts and growing demand for advanced imaging seen as key growth drivers that support RadNet's long term story and current valuation framework.
CVS
US$73.49
CVS Health
7D
4.9%
1Y
15.4%

CVS: Medicare Advantage Turnaround And FTC Settlement Will Support Earnings Recovery

Analysts have slightly raised their fair value estimate for CVS Health to $96.50, citing improving clarity around potential FTC settlements and a perceived Medicare Advantage turnaround. These developments could support a higher future P/E multiple, even with more conservative assumptions for revenue growth and profit margins.
DVA
US$145.58
DaVita
7D
-5.7%
1Y
-2.6%

DVA: Ongoing Buybacks And Revised P/E Assumptions Will Shape Future Returns

DaVita’s analyst price target has been revised to $151.71, with analysts pointing to updated assumptions around the discount rate and forward P/E as key drivers of the refreshed outlook. Analyst Commentary Recent Street research on DaVita points to a cluster of higher price targets, with several firms revisiting their models around discount rates and forward P/E assumptions.
INNV
US$7.61
InnovAge Holding
7D
-3.8%
1Y
168.9%

INNV: Raised Outlook And Model Assumptions Will Likely Prove Overly Optimistic

Analysts have lifted their price target on InnovAge Holding to $7 from $5, reflecting updated models that refine assumptions around fair value, discount rate, revenue growth, profit margin and future P/E. Analyst Commentary Bullish Takeaways Bullish analysts view the lift in the price target to $7 as a sign that updated assumptions on fair value and discount rates support a higher implied equity valuation.
PRE
US$19.68
Prenetics Global
7D
-4.0%
1Y
422.0%
BLLN
US$79.36
BillionToOne
7D
14.1%
1Y
n/a